US Patent No: 6,204,260

Number of patents in Portfolio can not be more than 2000

Non-peptidyl vasopressin V1a antagonists

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

This invention provides methods and 2-(azetidin-2-on-1-yl)acetic acid derivatives for the antagonism of the vasopressin V.sub.1a receptor.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ELI LILLY AND COMPANYINDIANAPOLIS, IN3414

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bruns, Jr Robert F Carmel, IN 15 100
Cooper, Robin DG Indianapolis, IN 1 16
Dressman, Bruce A Indianapolis, IN 40 138
Hunden, David C Carmel, IN 9 103
Kaldor, Stephen W San Diego, CA 76 466
Koppel, Gary A Indianapolis, IN 55 242
Rizzo, John R Indianapolis, IN 8 28
Skelton, Jeffrey J Indianapolis, IN 4 39
Steinberg, Mitchell I Indianapolis, IN 23 244

Cited Art

Patent Info (Count) # Cites Year
 
ELI LILLY AND COMPANY (2)
4,734,498 3.beta.-succinimidoazetidinones as chiral intermediates 10 1986
4,772,694 Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates 7 1986
 
MERCK SHARP & DOHME CORP. (2)
5,952,321 Substituted azetidinones as anti-inflammatory and antidegenerative agents 20 1996
5,846,966 Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors 49 1997
 
AMERICAN CYANAMID COMPANY (1)
5,480,987 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them 3 1994
 
NAEJA PHARMACEUTICAL INC. (1)
5,986,108 4-substitued-3-[1 or 2 amino acid residue]-azetidin-2-one derivatives useful as cysteine proteinase inhibitor 3 1997
 
NORTHWESTERN UNIVERSITY (1)
5,373,089 Oxytocin antagonist 5 1993
 
TAKEDA CHEMICAL INDUSTRIES, LTD. (1)
4,751,299 Optically active .beta.-lactams and method of their production 5 1984

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
TARGEGEN, INC. (8)
7,208,493 Vasculostatic agents and methods of use thereof 9 2003
7,456,176 Benzotriazine inhibitors of kinases 3 2005
7,528,143 Bi-aryl meta-pyrimidine inhibitors of kinases 7 2006
7,691,858 Kinase inhibitors and methods of use thereof 3 2007
7,825,246 Bi-aryl meta-pyrimidine inhibitors of kinases 2 2007
8,133,900 Use of bi-aryl meta-pyrimidine inhibitors of kinases 1 2008
8,138,199 Use of bi-aryl meta-pyrimidine inhibitors of kinases 1 2008
8,372,971 Heterocyclic compounds and methods of use 0 2011
 
AZEVAN PHARMACEUTICALS, INC. (4)
7,119,083 .beta.-Lactamyl vasopressin V.sub.1a Antagonists 2 2002
7,268,125 .beta.-lactamyl vasopressin V.sub.1a antagonists 2 2006
8,048,874 Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists 1 2006
8,426,400 β-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists 0 2011
 
REVAAX PHARMACEUTICALS, LLC (3)
6,627,625 Treatment of behavioral disorders with .beta.-lactam compounds 8 2000
6,610,681 Neurotherapeutic clavulanate composition and method 2 2000
7,842,683 Neurotherapeutic compositions and method 0 2008
 
MEDALLION BIOMEDICAL, LLC (1)
7,179,907 Antibiotic compounds 2 2002